Neonode transitions to automotive production amid rising operating costs
Neonode (NASDAQ:NEON) reported first-quarter revenue from continuing operations of $0.6 million, a 19.7% increase compared to the same period in 2025.
Neonode (NASDAQ:NEON) reported first-quarter revenue from continuing operations of $0.6 million, a 19.7% increase compared to the same period in 2025.
FedEx (NYSE:FDX) announced that it will execute the separation of its freight business through a tax-free, pro rata dividend of 80.1% of the outstanding shares of the newly formed FedEx Freight Holding Company.
Compass Pathways (NASDAQ:CMPS) reported first-quarter net income of $91.2 million, or $0.71 per basic share, a dramatic reversal from the $17.9 million loss recorded in the same period last year.
DarioHealth (NASDAQ:DRIO) posted first-quarter revenue of $5.6 million, a 6.7% increase from the fourth quarter of 2025.
Nebius Group (NASDAQ:NBIS) reported a first-quarter profit of $621.2 million, or $2.11 per share.
CTW (NASDAQ:CTW) announced Wednesday that revenue for the six months ending January 31, 2026, reached $40.9 million, a 1% decline from the $41.2 million reported in the prior-year period.
Costamare Bulkers (NYSE:CMDB) reported first-quarter net income of $9.9 million, or $0.41 per share.
Valens Semiconductor (NYSE:VLN) posted first-quarter revenue of $16.9 million, edging past its guidance range of $16.3 million to $16.7 million.
Pfizer (NYSE:PFE) announced Wednesday that European regulators have cleared Hympavzi for adolescents and adults with hemophilia A or B with inhibitors, marking a significant expansion for the non-factor therapy in the 27 EU member states, Iceland, Liechtenstein, and Norway.
Arbutus Biopharma (NASDAQ:ABUS), a clinical-stage biopharmaceutical company focused on infectious diseases, reported its financial results for the first quarter ended March 31, 2026.
BrainsWay (NASDAQ:BWAY) delivered a powerful first-quarter 2026 performance, marked by a 35% year-over-year revenue increase to $15.5 million.
Altimmune (NASDAQ:ALT), a clinical-stage biopharmaceutical company developing treatments for metabolic and liver diseases, reported its first-quarter 2026 financial results and provided a business update.